SCHEMBL5239540

SCHEMBL5239540

CCCCOc1c(CO)n(Cc2ccco2)c(=O)c2cc(Cl)c(Cl)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.42
ALDH1A1 P00352 8/20 0.41
POLB P06746 5/20 0.41
KMT2A Q03164 3/20 0.41
PKM P14618 3/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 5/20 0.39
LMNA P02545 4/20 0.39
USP2 O75604 3/20 0.38
MAPK1 P28482 2/20 0.38
ALOX15 P16050 1/20 0.38
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
TP53 P04637 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5231274 0.89 TSHR (0.41) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5238814 0.87 USP2 (0.42) TSHRALDH1A1POLBKMT2APKM
SCHEMBL6109221 0.86 TSHR (0.46) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5235937 0.85 MAPT (0.42) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5239221 0.84 PDE4A (0.41) TSHRALDH1A1KDM4ELMNAMAPK1
SCHEMBL6108951 0.84 TP53 (0.38) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5233289 0.83 KDM4E (0.48) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5238818 0.82 LMNA (0.40) TSHRALDH1A1POLBKMT2APKM
SCHEMBL5231965 0.79 DPP4 (0.37) TSHRALDH1A1SMN1; SMN2TDP1L3MBTL1
SCHEMBL6108948 0.78 KMT2A (0.38) TSHRALDH1A1POLBKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
EP-1355886-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
WO-2002062764-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 TSHR 2475/4885ALDH1A1 387/4885POLB 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.